Christopher Boerner - Bristol Myers President
| BMY Stock | USD 58.23 0.35 0.60% |
President
Dr. Christopher S. Boerner, Ph.D., is Executive Vice President and Chief Commercial Officer of the Company. He most recently served as the Companys head of international markets from October 2017 to August 2018. He joined the Company in February 2015 as head of the U.S. commercial organization and served in that role until October 2017. Prior to joining the Company, he was with Seattle Genetics, Inc., where he served as executive vice president of commercial from 2014 to 2015 and senior vice president of commercial from 2012 to 2014. Before joining Seattle Genetics, Mr. Boerner was with Dendreon Corporationrationration, where he led the marketing team. From 2002 to 2010, he worked at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including director of marketing on Avastin, director of Avastin franchise strategy and associate director of oncology market development. since 2018.
| Age | 53 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | Route 206 & Province Line Road, Princeton, NJ, United States, 08543 |
| Phone | 609 252 4621 |
| Web | https://www.bms.com |
Bristol Myers Management Efficiency
The company has Return on Asset of 0.0607 % which means that on every $100 spent on assets, it made $0.0607 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3133) %, meaning that it generated no profit with money invested by stockholders. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bristol Myers' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.14 in 2024, whereas Return On Tangible Assets are likely to drop 0.15 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jennifer Zachary | Merck Company | 46 | |
| Robert Davis | Merck Company | 54 | |
| Melissa Thomas | Cinemark Holdings | 44 | |
| Brett Mattison | Gold Fields Ltd | 41 | |
| Albert Bourla | Pfizer Inc | 59 | |
| Angela Hwang | Pfizer Inc | 58 | |
| Lisa Gibbs | Amtech Systems | 49 | |
| Cristal Downing | Merck Company | 55 | |
| Don Harton | Cinemark Holdings | 66 | |
| Frank DAmelio | Pfizer Inc | 66 | |
| Mikael Dolsten | Pfizer Inc | 62 | |
| Martin Preece | Gold Fields Ltd | 59 | |
| Richard Butcher | Gold Fields Ltd | 56 | |
| Taryn Harmse | Gold Fields Ltd | 47 | |
| Michael Nally | Merck Company | 44 | |
| Luis Rivera | Gold Fields Ltd | 54 | |
| Avishkar Nagaser | Gold Fields Ltd | 41 | |
| Constantine Markakis | Dorian LPG | N/A | |
| Nigel GreyTurner | Dorian LPG | N/A | |
| Alfred Baku | Gold Fields Ltd | 53 | |
| Dawn Rogers | Pfizer Inc | 54 | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | 0.0607 |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jitendra Tyagi, Head India | ||
| Ann Powell, Chief Human Resource Officer, Senior Vice President, Member of the Leadership Team | ||
| Karen Vousden, Independent Director | ||
| Adam Dubow, Senior Vice President, Chief Compliance Officer and Ethics Officer, Member of the Leadership Team | ||
| Michael Bonney, Independent Director | ||
| Robert Bertolini, Independent Director | ||
| Catherine Owen, Senior Markets | ||
| Paula Price, Independent Director | ||
| Gerald Storch, Independent Director | ||
| Sandra Esq, Executive Counsel | ||
| Louis Schmukler, Executive Vice President, President - Global Product Development and Supply, Member of the Leadership Team | ||
| Christopher Boerner, Executive Vice President and Chief Commercial Officer, Member of the Leadership Team | ||
| Phyllis Yale, Independent Director | ||
| Kimberly Jablonski, Chief Officer | ||
| John Elicker, Senior Vice President - Corporate Affairs and Investor Relations | ||
| David Elkins, Executive Vice President and Chief Financial Officer Member of the Leadership Team | ||
| BCH BM, Ex Devel | ||
| Karen Santiago, Senior Vice President, Corporate Controller | ||
| Rupert Vessey, Executive Vice President - Research and Early Development, Member of the Leadership Team | ||
| Giovanni Caforio, Chairman of the Board, Chief Executive Officer | ||
| Vicki Sato, Lead Independent Director | ||
| Manuel Medina, Independent Director | ||
| Nadim Ahmed, Executive Vice President and President - Hematology | ||
| Julia Haller, Independent Director | ||
| Cari Gallman, VP Officer | ||
| Joseph Eid, Senior Vice President and Head of Global Medical Affairs, Member of the Leadership Team | ||
| Derica Rice, Independent Director | ||
| Dinesh Paliwal, Independent Director | ||
| Theodore Samuels, Lead Independent Director | ||
| Matthew Emmens, Independent Director | ||
| Ann Judge, Chief Human Resource Officer, Senior Vice President Member of the Leadership Team | ||
| Timothy Power, VP Relations | ||
| Sandra Leung, Executive Vice President, General Counsel, Member of the Leadership Team | ||
| Adam Lenkowsky, Chief VP | ||
| Ahn Poole, Executive Officer | ||
| Paul Autenried, Executive Vice President, Chief Information Officer, Member of the Leadership Team | ||
| Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, Member of the Leadership Team | ||
| Tim Power, Vice President of Investor Relations | ||
| Giovanni MD, Executive Board | ||
| Samit MD, Executive Development | ||
| Greg Meyers, Executive Vice President Chief Digital and Technology Officer, Member of the Leadership Team | ||
| Kathryn Metcalfe, Executive Vice President - Corporate Affairs Member of the Leadership Team | ||
| Peter Arduini, Independent Director | ||
| Michelle Weese, Executive Vice President - Corporate Affairs, Member of the Leadership Team | ||
| Joseph Eiden, Head Affairs | ||
| Elizabeth Mily, Executive Vice President - Strategy and Business Development, Member of the Leadership Team |
Bristol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | 0.0607 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 160.7 B | ||||
| Shares Outstanding | 2.03 B | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 78.20 % | ||||
| Number Of Shares Shorted | 23.42 M | ||||
| Price To Earning | 24.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.